Press release
Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
- Dose escalation study clears the path to a comprehensive evaluation of Compugen's DNAM axis hypothesis of triple blockade of PVRIG, TIGIT and PD-1 pathways
About this update from Compugen Ltd.
[{"type":"text","content":"- Dose escalation study clears the path to a comprehensive evaluation of Compugen's DNAM axis hypothesis of triple blockade of PVRIG, TIGIT and PD-1 pathways in select biomarker informed indications\n - Triple combination of COM701, nivolumab and BMS-986207 (anti-TIGIT antibody) was well tolerated with a favorable safety and toxicity profile\n - Translational data support potent immune activation following triple blockade across measures of immune function\n - Best response of stable disease in heavily pretreated heterogenous all-comer patient population with a median of 10 and up to 19 prior therapies\n - Expansion cohorts enrolling in select biomarker-informed tumor types\n - Management will discuss the preliminary results as part of the Q3 earnings call, today at 8:30am ET\n\n\nHOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary results from its ongoing Phase 1/2 triple combination dose escalation study evaluating the combination of COM701, Compugen's potentially first-in-class anti-PVRIG antibody, with Bristol Myers Squibb's (NYSE: BMY) anti-PD-1, Opdivo® and BMS-986207, an investigational anti-TIGIT antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 10-14, 2021.\n\"The preliminary data reported from this Phase 1/2 triple combination dose escalation study demonstrate that triple blockade of PVRIG, TIGIT and PD-1 is well tolerated, with a favorable safety and toxicity profile and a maximum tolerated dose was not reached.\" said principal investigator and presenting author Ecaterina Elena Dumbrava, M.D., Assistant Professor of Investigational Cancer Therapeutics, at the University of Texas MD Anderson Cancer Center. \"The totality of the data is encouraging and I look forward to enrolling patients to the expansion cohorts in select tumor types to potentially address the unmet need of patients who do not respond to existing immune checkpoint inhibitors.\"\nAnat Cohen-Dayag, Ph.D., President and CEO of Compugen, added, \"Demonstrating a favorable safety profile in the triple combination study is an important milestone, which enables further development of our differentiated blockade of the DNAM axis. We are excite...